Compare Quest Diagnostics Inc (DGX) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs BlackRock TCP Capital Corp — how do they compare? Quest Diagnostics Inc trades at $204.12 (market cap $22.80B), while BlackRock TCP Capital Corp trades at $3.32 (market cap $265.55M). The key difference: Quest Diagnostics Inc is far larger — about 85.9× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays the higher dividend (26.54%). Which is the better fit depends on your goals.
| DGX | TCPC | |
|---|---|---|
Market Cap | $22.80B | $265.55M |
Sector | Health | Financials |
52-Week High | $216.02 | $7.84 |
52-Week Low | $166.42 | $3.14 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | 26.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
TCPC trades at $3.15, down 3.37% today, with a bearish technical signal and negative revenue trends. The company reported a net loss of $88.93M in 2025 despite a 112% net income margin, driven by negative revenue. Analyst consensus shows mixed sentiment with 31% buy ratings, while recent news includes a Zacks upgrade and upcoming Q2 earnings on August 6, 2026.
The outlook remains challenging with persistent negative revenue and profitability issues. Investment opportunities include the low P/B ratio of 0.47 and dividend yield, but risks include ongoing losses, shareholder litigation, and bearish technical indicators. The stock faces significant fundamental headwinds despite some analyst optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
